Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | CPX-351 for secondary AML: pharmacokinetics, administration & impact on treatment

Jeffrey Lancet • 1 Mar 2019
ISAL 2019
Leukemia CPX-351 Cytarabine Daunorubicin

Jeffrey Lancet, MD, of the Moffitt Cancer Center, Tampa, FL, talks to us all about CPX-351, a recent innovation in conventional chemotherapy. CPX-351 is a liposomal formulation of the optimal ratio of cytarabine and daunorubicin, which was FDA approved in August 2017 for the frontline treatment of secondary acute myeloid leukemia (AML) and EMA approved in September 2018. Dr Lancet discusses the novel nature of this delivery system and its administration, and how this affects pharmacokinetics and treatment. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Jeffrey Lancet

The role of transfusion support in older patients with AML no longer receiving active therapy
1:39
The role of transfusion support in older patients with AML no longer receiving active therapy
Jeffrey Lancet • 6 May 2026
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
2:44
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
Jeffrey Lancet • 6 May 2026
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
2:52
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
Jeffrey Lancet • 6 May 2026
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
2:13
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
Jeffrey Lancet • 6 May 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals